Global Vitiligo Treatment Market Overview:
Vitiligo is a skin disease that prevents through a long-term period, also patches the skin to lose their colour. The skin patches that are affected by the disease Vitiligo become white. This kind of disease happens because of melanocytes within the skin die off. Moreover, skin pigmentation, melanin, due to which skin has its colour, protection from sun UV rays this all happens because of melanocyte cells. Hence the deficiency of this pigment can create diseases like this. Therefore, the growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing disease awareness and expected approval of Vitiligo treatment are some of the driving forces for the growth of this market. In addition to that, the key players are focusing on adopting collaboration and acquisition strategies.
- Rising Demand for Innovative and Modern Treatment Options for Vitiligo
- Increasing Number of Vitiligo Patients to Favour Growth in the Asia Pacific
- Adopting Collaboration and Acquisition Strategies to Develop and Commercialize Novel Vitiligo Treatment Drugs in Order to Expand their Product Portfolio
- Shortage of Dermatologists and Available Treatments Having a Longer Duration of Times
- Reduction in the Diagnosis Rate may Hamper the Vitiligo Drug Market Growth
- Increasing Research and Development Activities Related to Vitiligo Treatment is Expected to Facilitate the Growth of the Market over the Forecast Period
- Lack of Awareness Regarding the Available Vitiligo Treatment
- Counterfeit of these Vitiligo Treatment
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Boston Pharmaceuticals (United States), Incyte (United States), Astellas Pharma (Japan), Bausch Health (Canada), Baxter (United States), Pfizer (United States), STRATA Skin Sciences (United States), Dr. Reddy's Laboratories (India), Bristol-Myers Squibb (United States), Celgene (United States) and Clinuvel Pharmaceuticals (Australia). Analyst at AMA Research see United States Players to retain maximum share of Global Vitiligo Treatment market by 2026. Considering Market by Drugs, the sub-segment i.e. ARN-4079 will boost the Vitiligo Treatment market. Considering Market by Drug Class, the sub-segment i.e. Calcineurin Inhibitors will boost the Vitiligo Treatment market.
Latest Market Insights:
In October 2018, Boston Pharmaceutical entered into a licensing agreement with GlaxoSmithKline for the development and commercialization of phase 1 drug products for the treatment of vitiligo.
In 2018, Boston Pharmaceutical expanded its product pipeline by adding a topical formulation called GSK3183475 from GlaksoSmith Kline, a small molecule inhibitor used in the treatment of vitiligo and psoriasis, currently in phase 1 clinical trial.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Vitiligo Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Vitiligo Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Vitiligo Drug and Surgical Instruments Manufactures, Potential Investors, Government Bodies and Associations, Up and Down Stream Vendors, Private Research Organizations, Suppliers and Distributors and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.